Indian Pharmacopoeia Commission signs MoU with UP Promote Pharma Council
On 14 July 2026, at the YEIDA MedTech Investors Meet in Greater Noida, the Indian Pharmacopoeia Commission (IPC) signed an MoU with the Uttar Pradesh Promote Pharma Council (UPPPC) on quality standards and drug-safety reporting. On 23 July it signed one with Dr. Shakuntala Misra National Rehabilitation University, Lucknow, and renewed another with CSIR-CIMAP.
- Date
- 14 Jul 2026 (UPPPC); 23 Jul 2026 (DSMNRU, CSIR-CIMAP)
- IPC
- autonomous body under the Health Ministry
- Venue
- India Expo Mart, Greater Noida (YEIDA MedTech meet)
- DSMNRU MoU
- assistive-device testing; sign-language pharmacovigilance module
- CSIR-CIMAP MoU
- renewed; herbal medicine standards
The IPC MoUs with UP bodies: what happened?
UP wants pharma and medical-device units around YEIDA. Factories alone are not enough; medicines and devices must meet quality standards and any harm must be reported. IPC sets these standards.
- The Indian Pharmacopoeia Commission (IPC) signed an MoU with the Uttar Pradesh Promote Pharma Council (UPPPC) at the YEIDA MedTech Investors Meet on 14 July 2026 at India Expo Mart, Greater Noida [PIB].
- They will work on quality standards, pharmacovigilance and materiovigilance awareness, joint training, and digital tools for MSMEs to report adverse events [PIB].
- On 23 July IPC also signed an MoU with Dr. Shakuntala Misra National Rehabilitation University, Lucknow, on testing assistive devices and a pharmacovigilance module in sign language, and renewed one with CSIR-CIMAP on herbal medicine standards [PIB].
What will each MoU do?
| Partner | Focus |
|---|---|
| UPPPC | quality standards, awareness of Indian Pharmacopoeia, pharmacovigilance and materiovigilance, joint training, digital adverse-event reporting tools for MSMEs |
| DSMNRU, Lucknow | protocols to test quality, safety and performance of assistive devices; pharmacovigilance training in sign language |
| CSIR-CIMAP | medicinal plant research, standardisation and quality of herbal medicines |
What can Prelims ask on the IPC MoUs with UP bodies?
- IPC: autonomous institution under the Ministry of Health & Family Welfare.
- Pharmacovigilance = tracking side effects of medicines; materiovigilance = of medical devices.
- DSMNRU is in Lucknow; CSIR-CIMAP works on medicinal and aromatic plants.
Read all of July 2026 in the monthly UP current affairs compilation →
How to use this in Mains
- Use YEIDA MedTech meet as an example of UP's sector-specific investment push.
- Quality regulation (pharmacovigilance) is the other half of an industrial policy.
- The DSMNRU MoU fits answers on disability inclusion in UP.
Quotable data pointIPC-UPPPC MoU signed on 14 July 2026 at India Expo Mart, Greater Noida [PIB].
PIB: IPC signs MoU with UPPPC
Exam angle
GS-VI: UP pharma and medtech push around YEIDA. GS-V: the sign-language module helps persons with disabilities report drug reactions.
Practice MCQs
Original practice questions (not PYQs).
Materiovigilance refers to monitoring adverse events linked to
Answer (b) & explanation
PIB, 15 Jul 2026: IPC-UPPPC MoU promotes awareness of pharmacovigilance and materiovigilance.
Questions students ask about this
What is the IPC-UPPPC MoU about?
Quality standards, drug and device safety reporting, joint training and digital reporting tools for MSMEs in UP's pharma and medical-device sector.
Where was it signed?
At the YEIDA MedTech Investors Meet, India Expo Mart, Greater Noida, on 14 July 2026.
What will the DSMNRU MoU do?
Develop tests for assistive devices and a pharmacovigilance training module in sign language.
Keep studying
Official source: PIB: IPC signs MoU with UPPPC
facts from cited sources only; numbers machine-checked against source text; faculty review pending